

FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Pancreatic Cancer

Protocol-ID: 47 V1.4 (Complete), FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Pankreas-Ca

Indication(s)

• Pancreatic Cancer; ICD-10 C25.-

Protocol classification

- Classification: current standard
- Intensity: Standard dose
- Therapy mode: First line
- Therapy intention: palliative

Cycles

Cycle length 14 days, recommended cycles: 12

Risks

- Emetogenicity (MASCC/ESMO): moderate (30-90%)
- Neutropenia: very high (>41%) Grade 3 and 4; 42.5% with G-CSF
- Febrile Neutropenia: intermediate (10-20%) Grade 3 and 4; 1 death, 42.5% with G-CSF
- Thrombocytopenia below 50 000/µl: low (<10%)
- Anemia Hb below 8g/dl: moderate (6-15%)
- Diarrhea: CTC AE °3-4: 12.7%
- Fatigue: CTC AE °3-4: 23.6%
- Vomiting: CTC AE °3-4: 14.5%
- Thromboembolic Event: CTC AE °3-4: 6.6%
- Neuropathy: CTC AE °3-4: 9.0%
- Increase Aminotransferases: CTC AE °3-4: 7.3%

Therapy

Hydr	ation: Balanced Crystalloid Solution						HYD
Acce	ss: peripheral venous						
Hydra	ation before, during, or after antitumor therapy						
Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure	
1	Balanced Crystalloid Solution	500 ml		i.v.	60 min	60 min before Oxaliplatin (d1)	

FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Pankreas-Ca PID 47 V1.4

Antiemesis: Emetogenicity moderate, GRAN i.v., DEXA i.v.

Access: peripheral venous

ASCO 2015, DGHO 2016, DKG 2016, MASCC/ESMO 2016, if palonosetron not available

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Dexamethasone	8 mg	NaCI 0.9% 50 ml	i.v.	5 min	30 min before Oxaliplatin (d1)
1	Granisetron	1 mg	NaCl 0.9% 50 ml	i.v.	5 min	15 min before Oxaliplatin (d1)
or oth	er 5-HT3 antagonist					
2-3	Dexamethasone	8 mg		p.o.		1-0-0-0

Antineoplastic therapy: FolFIrinOx

Access: central venous

5-FU	, folinic acid, irinoteca	an, and oxaliplatin in pancre	eatic cancer			
Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
1	Oxaliplatin	85 mg/m ² BSA	Dextrose 5% 500 ml	i.v.	2 h	Sequence
1	Folinic acid	400 mg/m ² BSA	NaCl 0.9% 250 ml	i.v.	2 h	Sequence
1	Irinotecan	180 mg/m ² BSA	NaCl 0.9% 250 ml	i.v.	90 min	90 min before Fluorouracil (d1)
Irinot	ecan is administered	30 minutes after the start of	f the folinic acid infusion in para	allel with	folinic acid.	
1	Fluorouracil	400 mg/m ² BSA	none	i.v.	1 min	Sequence
Bolu	application					
1	Fluorouracil	2400 mg/m ² BSA	NaCl 0.9% 500 ml	i.v.	46 h	Sequence
The	volume of the corrier	colution refere to innotiont t	horopy with infusion pumps M/			imps or ambulatory systems, a different volume

The volume of the carrier solution refers to inpatient therapy with infusion pumps. When using syringe pumps or ambulatory systems, a different volume (e.g. 100 ml) can be used.

Hema	topoietic growth factors	s: FN risk 10-20%,	G-CSF long-act	ting, pegyla	ted		HW
Acces	s: - none -						
	,		-			anemia, lymphocytopenia < 700/μl, hypalbuminemia, symptomatic tumor disease (DKG 2016)	
_	.	_					
Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure	
Day 4	Substance Pegfilgrastim	Dosage 6 mg	Solution	Appl.	Inf. time Bolus	Procedure 24 h after Fluorouracil (d1)	

Substance links

Links to substances are found here.

Concomitant therapy supplements

If a cholinergic syndrome occurs during Irinotecan, according to the summary of product characteristics, 0.25 mg Atropine sulphate should be administered subcentrally; if a history of cholinergic syndrome is known, Atropine should be administered prophylactically before Irinotecan.

Loperamide can be used to treat the onset of delayed diarrhea.

Notes

Increase the risk of febrile neutropenia to medium, as one death due to febrile neutropenia occurred in the study. Filgrastim application was required in 42.5% of patients.

For patients with a response, 6 months of therapy was recommended in the literature.

Cycle diagram

СТХ

FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Pankreas-Ca PID 47 V1.4

Hydration: Balanced Crystalloid Solution

	Week 1 / d						
Substance	1	2	3	4	5	6	7
Balanced Crystalloid Solution (i.v.)							

Antiemesis: Emetogenicity moderate, GRAN i.v., DEXA i.v.

	Week 1 / d						
Substance	1	2	3	4	5	6	7
Dexamethasone (i.v.)							
Granisetron (i.v.)							
Dexamethasone (p.o.)							

Antineoplastic therapy: FolFIrinOx

			We	ek 1	/ d		
Substance	1	2	3	4	5	6	7
Oxaliplatin (i.v.)							
Folinic acid (i.v.)							
Irinotecan (i.v.)							
Fluorouracil (i.v.)							
Fluorouracil (i.v.)							

Hematopoietic growth factors: FN risk 10-20%, G-CSF long-acting, pegylated

	Week 1 / d						
Substance	1	2	3	4	5	6	7
Pegfilgrastim (subc)							

Cycles

Cycle length 14 days, recommended cycles: 12

Controls:

- · Blood count: on day 1 and subsequently weekly
- DPD Exclude deficiency: Uracil levels or DPD gene mutations.
- Day 1: Anamnesis and clin. examination regarding neuropathy
- Day 1: GOT, GPT, GGT, Bilirubin, AP, Cholinesterase Irinotecan: increased risk of toxicity due to decreased hepatic clearance with elevated bilirubin between 1.5 and 3 times the norm, see summary of product characteristics for dose adjustment. Do not administer if bilirubin > 3 times normal elevated. Regular blood count and bilirubin checks in hepatic insufficiency. Fluorouracil: liver monitoring during therapy. Severe hepatic insufficiency is a contraindication.
- Day 1: Creatinine, glomerular filtration rate (GFR) Oxaliplatin: no use in patients with severe renal impairment creatinine clearance < 30 ml/min. Irinotecan: no studies on renal insufficiency, use in renal insufficiency is therefore not recommended. Fluorouracil: control of retention values

Dose adjustment

- Fluorouracil
 - for Bone Marrow Insufficiency: Platelets
 >100,000 T./µl- 100% dose; 70000-100000 T./µl- 75% dose; 50000-70000 T./µl- 50% dose; <50000 T/µl STOP!</p>

 for Bone Marrow Insufficiency: Leukocytes
 - for Bone Marrow Insufficiency: Leukocytes
 >4000 L./μl- 100% dose; 3000-4000 L./μl- 75% dose; 2000-3000 L./μl- 50% dose; <2000 L./μl STOP!
- Oxaliplatin
 - for Renal Failure: Glomerular Filtration Rate (GFR)

No data on patients with severe renal impairment (contraindication if creatinine CL < 30ml/min). In moderate renal impairment, close monitoring and dose adjustment according to toxicity. In case of mild renal impairment no dose adjustment necessary

for Bone Marrow Insufficiency: Neutrophils

In case of neutrophil count< 1500/µl, the next treatment cycle must be postponed until acceptable values are reached. Before starting oxaliplatin treatment and each new cycle, a complete blood count including differential white blood cell count is required.

• for Bone Marrow Insufficiency: Platelets

 $\label{eq:FOLFIRINOX} FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400), Pankreas-Ca PID 47 V1.4 \\ \end{tabular} If the platelet count is <50000/µl, the next treatment cycle must be postponed until acceptable values are reached. \\ \end{tabular} Prior to initiation of oxaliplatin treatment and each new cycle, a complete blood count including white blood cell differential must be performed. \\ \end{tabular}$

Original indication

Pancreatic carcinoma (adeno-), metastatic, ECOG 0-1

Original author

Conroy, Thierry (2011)

Origin

Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup

References

- Conroy T, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.; N Engl J Med 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923. PMID: 21561347. [PMID]
- Conroy T, Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer, A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study; J Clin Oncol 2005 Feb 20;23(6):1228-36. doi: 10.1200/JCO.2005.06.050. PMID: 15718320. [PMID]
- Ducreux M, Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015 Sep;26 Suppl 5:v56-68. doi: 10.1093/annonc/mdv295. PMID: 26314780. [PMID]

Recommendations

- 11/2023: European Society for Medical Oncology
- 06/2023: National Comprehensive Cancer Network

Status

Valid since 2024-09-20, Version 1.4, last updated 2024-09-17

Last modification: V1.4: Correction of relative times and days Pegfilgrastim. V1.3: Correction title, correction antiemesis V1.2: New Cato import due to cycle counting and diagnosis assignment by ICD-10 codes. V1.1: Cato test done. V1.0: Run times and substance sequence according to primary literature.

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.



The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.